Worldwide, hepatitis B virus is the major risk factor for hepatocellular carcinoma (HCC), owing to its high prevalence in the developing world. Hepatitis B virus vaccination programs have and will ...

Advanced hepatocellular carcinoma (HCC) with pulmonary metastasis (PM) has a poor prognosis, and optimal treatment strategies remain controversial. This study compared pulmonary metastasectomy and ...

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide. Multiple treatment modalities ...

Researchers sought to test the performance of a deep learning model system using longitudinal magnetic resonance imaging (MRI) in predicting early recurrence in patients with hepatocellular carcinoma.

Investigators conducted a systematic review and meta-analysis of more than 100 studies primarily from Asia, Europe, and the US to evaluate hepatocellular carcinoma outcomes on the basis of age.

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, with over 70% of patients diagnosed at ...

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...